<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989751</url>
  </required_header>
  <id_info>
    <org_study_id>KY2019-409</org_study_id>
    <nct_id>NCT04989751</nct_id>
  </id_info>
  <brief_title>A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China</brief_title>
  <official_title>A Multicenter Phenotype-Genotype Analysis of Limb Girdle Muscular Dystrophy Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Limb-girdle muscular dystrophies (LGMD) are a series of rare progressive genetic disorders&#xD;
      that are characterized by wasting and weakness of the voluntary proximal muscles. The onset&#xD;
      of the disease is usually at young age, and most patients will be wheelchair-bound due to the&#xD;
      progressive deterioration. Since currently genetic therapies for this disease are still&#xD;
      immature, better natural history and genotype-phenotype studies are needed for preparing&#xD;
      future therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is multicentered-based, prospective, and observational study, which mainly focuses on&#xD;
      the diagnosis and progression of limb-girdle muscular dystrophies (LGMD) in China. We collect&#xD;
      patient data including basic information, strength evaluations, genetic data,&#xD;
      electromyography results, pathology imaging from muscle biopsies, and MRIs. Previously&#xD;
      collected patient data may also be enrolled in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Change in mobility</measure>
    <time_frame>Baseline, Year 1, Year 3</time_frame>
    <description>The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle fat infiltration</measure>
    <time_frame>Baseline, Year 1, Year 3</time_frame>
    <description>The muscle-specific fat fraction can be calculated with special MRI sequences such as IDEAL or Dixon in the region of interest. Our previous study found that the fat fraction of semitendinosus positively correlated with the length LGMD R1/R2 duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motor performance</measure>
    <time_frame>Baseline, Year 1, Year 3</time_frame>
    <description>The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant patients with Duchenne Muscular Dystrophy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>LGMD</condition>
  <condition>LGMDR2</condition>
  <condition>LGMDR1</condition>
  <arm_group>
    <arm_group_label>LGMD patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Electromyography</intervention_name>
    <description>Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.</description>
    <arm_group_label>LGMD patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>IDEAL MRI</intervention_name>
    <description>Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.</description>
    <arm_group_label>LGMD patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Muscle tissue from biopsy, stored in -80 Â°C freezer&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients are mainly from neuromuscular diagnostic centers that participat this study in&#xD;
        China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Identified with variants regarding LGMD related genes revealed by genetic sequencing&#xD;
&#xD;
          -  Progressive weakness involving shoulder girdle and/or pelvic girdle&#xD;
&#xD;
          -  Myopathic changes in electromyography or in pathological studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Identified with variants in other genes (non-LGMD related) that may cause muscular&#xD;
             dystrophies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Chongbo Zhao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Chongbo Zhao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Observational</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

